Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative

1

The study compared long-term survival in operable HR+/HER2- breast cancer patients receiving neoadjuvant chemotherapy (NACT) versus adjuvant chemotherapy (ACT).
2

Data from 33,552 patients in the SEER database indicated that NACT was associated with significantly inferior overall survival (OS) and breast cancer-specific survival (BCSS) compared to ACT.
3

After propensity score matching, the 5-year OS for the NACT group was 87.4% compared to 91.8% for the ACT group, with significant statistical differences.
4

Multivariate analysis revealed higher risks of breast cancer-specific death and all-cause death in patients achieving objective response to NACT compared to ACT.
5

The findings suggest caution in selecting NACT for operable HR+/HER2- breast cancer patients at stage II and T3N1M0 due to inferior survival outcomes.

1